VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to ...

Prader-Willi syndrome is a rare genetic disease that causes poor feeding in infancy but later triggers insatiable hunger.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for central nervous system and oncology-related conditions. Its lead candidates, NDV-01 ...